$224.84 1.89 (0.85%)
19:56 EST AMGN Stock Quote Delayed 15 Minutes
Previous Close $224.84
Market Cap 148.78B
PE Ratio 71.38
Volume (Avg. Vol.) 2.10M
Day's Range 222.85 - 226.70
52-Week Range 166.30 - 244.99
Dividend & Yield 5.28 (2.35%)
AMGN Stock Predictions, Articles, and Amgen News
- From InvestorPlace
- From the Web
These healthcare stocks are worth selling now as Sanders rises in the polls and given his stance that prices should be cut in half.
Matt McCall predicts that 2020 will be a better year for U.S. cannabis stocks. He's also calling for a big rally in bitcoin.
Goldman Sachs analysts came out with three conviction buys on Monday. Here's what else happened in the stock market today.
Folks who haven’t been paying attention to the absolutely huge potential happening in biotech stocks right now -- both in the U.S. and other parts of the world -- have been put on notice.
The biggest risk to Amgen stock comes from health reform that might limit the number of drugs insurers pay for, creating price competition.
Biotech stocks are still out of favor because of macro uncertainties. But beneath that, investors may find companies trading at deep value.
Amgen's purchase of Celgenes blockbuster psoriasis drug, Otezla is likely to strengthen its position in the immunology space and boost Amgen stock.
Trade talks gave a lift to stocks, while Johnson & Johnson will be in focus after the close. Here's what happened in the stock market today.
Netflix, Amgen, Bristol-Myers Squibb, Aurora Cannabis and Foot Locker are our top stock trades for Tuesday. Here's how to trade them.
Celgene news for Thursday about it selling Otezla has CELG stock on the rise as it moves forward with the Bristol-Myers Squibb merger.
Options trading was buzzing on Tuesday, with Amgen, American Airlines and Apple all making notable moves. Here are the metrics that matter moving forward.
Matt McCall is extremely bullish on China and the big opportunities in several sectors, but Chinese biotech stocks top his list.
Q2 earnings season rolls on and Wall Street tries to not act disappointed by the early end to the latest round of U.S.-China trade talks. Thus, individual stock price action is uneven with all the focus going to a handful of names posting solid results.
If you’re looking for the next big thing in investing, these three down but not out biotech stocks are the way to go.
Navellier RatingsPowered by Portfolio Grader